Tackle respiratory infections year-round

Meet the challenges that this respiratory season will bring

As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems (1–3).

Diagnostic approaches using rapid molecular testing may help alleviate this burden (4,5). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.

Latest insights

Syndromic testing, QIAstat-Dx Rise, instrument

Take your diagnostics to new heights

Meet the QIAstat-Dx Rise, the new higher-throughput member of the QIAstat-Dx family. The QIAstat-Dx Rise combines a quick and easy workflow with random access capabilities for increased testing capacity. This powerhouse instrument is uniquely built to fit the needs of high-demand institutions, helping you test up to 160 samples per day with eight Analytical Modules.

DISCOVER THE QIASTAT-DX RISE

Detection of emerging SARS-CoV-2 Delta, Mu and Omicron variants

The QIAstat-Dx Respiratory SARS-CoV-2 Panel remains capable of detecting SARS-CoV-2 infections in light of the emergence of new coronavirus variants, including Omicron (B.1.1.529).

LEARN MORE

Illustration of the Coronavirus, schematic drawing of the virus

Discover respiratory testing resources

Adopting a syndromic diagnostic approach to serve the community during COVID-19

When COVID-19 struck in Northwest Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. She placed her trust in the QIAstat-Dx system to test for a wide range of pathogens, not just SARS-CoV-2, to help provide fast answers and peace of mind to her community.

read her story

Featured
–
explore syndromic respiratory testing

Don’t just test for SARS-CoV-2 this season

In this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero discusses the role of syndromic testing during the ongoing COVID-19 pandemic. He also addresses the importance of time to diagnosis and potential for co-infections during respiratory season.

Watch now

Don’t just test for SARS-CoV-2 this season

Uniquely powerful
–
our solution for syndromic testing

* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 22 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

Download the flyer

icon-callout-help

Ready to learn how syndromic testing with QIAstat-Dx can benefit your institution?

Contact an expert

Additional resources

*Some features require a QIAstat-Dx Connectivity plan; flexible plans are available to meet your lab’s needs

References

Hodjat, P., Christensen, P.A., Subedi, S., Bernard, D.W., Olsen, R.J. and Long, S.W. (2021) The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. medRxiv. doi: https://doi.org/10.1101/2021.05.27.21257940
Centers for Disease Control and Prevention Weekly U.S. Influenza Surveillance Report https://www.cdc.gov/flu/weekly/index.htm
Centers for Disease Control and Prevention Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States https://emergency.cdc.gov/han/2021/han00443.asp
European Centre for Disease Prevention and Control COVID-19 testing strategies and objectives https://www.ecdc.europa.eu/sites/default/files/documents/TestingStrategy_Objective-Sept-2020.pdf
Centers for Disease Control and Prevention Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.

The QIAstat-Dx Analyzer, QIAstat-Dx Rise and QIAstat-Dx Respiratory SARS-CoV-2 Panel are intended for in vitro diagnostic use.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.